Endothelin-1 (ET-1) is a potent vasoconstrictor hormone that has been identified as an important factor
responsible for the development of cardiovascular dysfunctions. ET-1 exerts its vasoconstrictor activity
through two pharmacologically distinct receptors, ETA and ETB that are found in vascular smooth muscle
cells (VSMCs) and the vasodilator activity through an ETB receptor located on endothelial cells. This study
aimed to show the impact of 1µM L-arginine (LA), 100µM tetrahydrobiopterin (BH4), and their combined
effect on ET-1 activity in both lead-treated and lead-untreated rat aortic rings. This means, investigating how
endothelial dysfunction reverses the role of nitric oxide precursor and cofactor. In this study, Rat aortic rings
have been pre-incubated with BH4, LA and their combination. Subsequently, the aortic rings were preincubated with 200µM N-Nitro-L-arginine methyl ester (L-NAME) and 0.5µM BQ-123. Then, the vascular
response to cumulative doses of rat ET-1 was analyzed in each of the above-mentioned groups (LA, BH4, LA
& BH4, L-NAME, BQ-123), in the presence and absence of lead acetate 1µM Pb (C2H3O2)2. ET-1 efficacy and
potency were significantly decreased in the presence of LA, BH4, and LA and BH4 combination in the untreated
group, while it significantly increased in the presence of lead. In the second trial of experiments ET-1 efficacy
markedly decreased in BQ-123- incubated cells in both lead-treated and untreated aortic rings. In the presence
of lead, the efficacy of ET-1 was raised with the use of L-NAME. In conclusion, LA and BH4 can be considered
pharmacological agents to alter the potency of ET-1-induced vasoconstriction and concomitantly lower blood
pressure.